Pfizer is seen to be adding to its valuations though it is over priced for now. Sales are pretty nice and so is the case with net profit. Debt free company with good track record, it should be added on each meaningful correction.
Note - Pharma related companies generally face the heat of US FDA since US FDA has deployed its inspectors in other countries including India n China to ensure that no violation whatsoever are committed by companies since it effect the health of human beings, at large. But, with such development med to long term investors should not get panicked. It can happen with any company, remember.